Q2 2025

Filed Aug 12, 2025 · 10-Q · 43 days after period end · 0001193125-25-178570

Q2 2025 · 10-Q

Revenue—

Net Income

$1.87M

no prior Q2 2024 on file

EPS, diluted—

Operating Income-$269,810—

Operating Cash Flowderived-$146,124—

Same quarter

no prior Q2 2024 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d after period end

Oaktree Acquisition Corp. III Life Sciences · CIK 2029769 · Engraved from SEC EDGAR